{"hands_on_practices": [{"introduction": "The cornerstone of guiding antibiotic therapy is the Minimum Inhibitory Concentration (MIC), yet its interpretation is not always straightforward. This exercise challenges you to apply the rigorous definition of MIC to a realistic scenario involving *Pseudomonas aeruginosa*, a pathogen notorious for complex resistance patterns. By analyzing data showing \"trailing\" and heteroresistance, you will uncover the critical limitations of standard susceptibility testing and appreciate its impact on clinical decision-making [@problem_id:4686043].", "problem": "An immunocompromised patient with ventilator-associated pneumonia due to Pseudomonas aeruginosa is tested by standard broth microdilution against a single antipseudomonal agent (Agent X). The inoculum is standardized to $5 \\times 10^{5}\\,\\mathrm{CFU/mL}$ in cation-adjusted Mueller–Hinton broth, and plates are read at $18\\,\\mathrm{h}$ under ambient air conditions. The doubling-dilution series spans $0.25, 0.5, 1, 2, 4, 8\\,\\mathrm{mg/L}$. The following observations are recorded at $18\\,\\mathrm{h}$:\n\n- At $0.25\\,\\mathrm{mg/L}$: heavy growth comparable to the positive control.\n- At $0.5\\,\\mathrm{mg/L}$: obvious growth.\n- At $1\\,\\mathrm{mg/L}$: visible growth with slight “haze” consistent with trailing.\n- At $2\\,\\mathrm{mg/L}$ and higher: no visible growth.\n\nA repeat read at $24\\,\\mathrm{h}$ notes a faint film at $2\\,\\mathrm{mg/L}$ and rare pinpoint colonies at $4\\,\\mathrm{mg/L}$. Population analysis profiling performed separately suggests a minority subpopulation with survival up to $4\\,\\mathrm{mg/L}$ at an estimated frequency of approximately $10^{-6}$.\n\nAssume the laboratory applies a pharmacokinetic/pharmacodynamic (PK/PD)-derived susceptible breakpoint of $B_{S} \\leq 1\\,\\mathrm{mg/L}$ and resistant if $> 1\\,\\mathrm{mg/L}$ for Agent X against Pseudomonas aeruginosa. Using the accepted definition that the Minimum Inhibitory Concentration (MIC) is the lowest antimicrobial concentration that prevents visible growth at the defined read time and standardized inoculum, determine the MIC for this isolate from the $18\\,\\mathrm{h}$ read.\n\nThen, explain how trailing growth and heteroresistance in Pseudomonas aeruginosa complicate endpoint determination and the application of clinical breakpoints such as $B_{S}$, connecting your discussion to first principles of standardized inoculum, read time, and the MIC definition.\n\nReport the MIC numerically in $\\mathrm{mg/L}$. No rounding beyond what is implied by the doubling-dilution series is required. Express the final numerical answer only, without units, in the answer box.", "solution": "The problem statement has been evaluated and is deemed valid. It is scientifically grounded in the principles of clinical microbiology and antimicrobial susceptibility testing, presenting a well-posed and objective scenario. The data provided—including inoculum size ($5 \\times 10^{5}\\,\\mathrm{CFU/mL}$), incubation time ($18\\,\\mathrm{h}$), drug concentrations, and observational results—are consistent with standardized laboratory practices (e.g., CLSI or EUCAST guidelines). The concepts of Minimum Inhibitory Concentration (MIC), clinical breakpoints ($B_{S}$), trailing growth, and heteroresistance are all fundamental to the field. The problem is self-contained and allows for a rigorous, deductive solution based on the provided definitions and data.\n\nThe primary task is to determine the Minimum Inhibitory Concentration (MIC) and then discuss the complications arising from the observed phenomena. The problem explicitly defines the MIC as \"the lowest antimicrobial concentration that prevents visible growth at the defined read time and standardized inoculum.\" The defined read time for the primary determination is $18\\,\\mathrm{h}$.\n\nThe observations from the broth microdilution assay at $18\\,\\mathrm{h}$ are as follows:\n- At a concentration of $0.25\\,\\mathrm{mg/L}$: heavy growth.\n- At a concentration of $0.5\\,\\mathrm{mg/L}$: obvious growth.\n- At a concentration of $1\\,\\mathrm{mg/L}$: visible growth.\n- At a concentration of $2\\,\\mathrm{mg/L}$: no visible growth.\n- At concentrations of $4\\,\\mathrm{mg/L}$ and $8\\,\\mathrm{mg/L}$: no visible growth.\n\nAccording to the provided definition, we must identify the lowest concentration in the tested series where no visible growth is observed. Reviewing the data, growth is present at $0.25\\,\\mathrm{mg/L}$, $0.5\\,\\mathrm{mg/L}$, and $1\\,\\mathrm{mg/L}$. The first concentration at which growth is completely inhibited is $2\\,\\mathrm{mg/L}$. Therefore, based on the $18\\,\\mathrm{h}$ read, the MIC for Agent X against this isolate of *Pseudomonas aeruginosa* is $2\\,\\mathrm{mg/L}$.\n\nThe second part of the task is to explain the complications introduced by trailing growth and heteroresistance in the context of first principles.\n\n1.  **First Principles and Their Role:**\n    -   **Standardized Inoculum:** The test begins with a standardized bacterial population, given as $5 \\times 10^{5}\\,\\mathrm{CFU/mL}$. The MIC is thus a population-level endpoint, not a single-cell endpoint. Its value reflects the concentration required to inhibit the growth of this specific number of bacteria to below the threshold of macroscopic visibility.\n    -   **Read Time:** The standard incubation period, here $18\\,\\mathrm{h}$, is a critical parameter. It is a kinetic checkpoint, not a true equilibrium endpoint. It must be long enough for susceptible organisms to multiply sufficiently in the control wells, but short enough to preclude the overgrowth of slow-growing resistant subpopulations, which might lead to a falsely elevated MIC.\n    -   **MIC Definition:** The definition relies on a subjective-visual \"all-or-none\" determination (\"visible growth\"). This binary output simplifies a complex biological reality of graded inhibition and subpopulation dynamics.\n\n2.  **Complication 1: Trailing Growth and Endpoint Determination:**\n    The observation at $1\\,\\mathrm{mg/L}$—\"visible growth with slight 'haze' consistent with trailing\"—exemplifies a major difficulty in reading MICs. Trailing (or the \"Schilder effect\") is the phenomenon of reduced, but persistent, growth across a range of antibiotic concentrations. It makes the \"all-or-none\" decision challenging. Is a \"haze\" considered growth? The problem statement specifies \"visible growth with a slight 'haze',\" which forces us to interpret it as growth, leading to an MIC of $2\\,\\mathrm{mg/L}$. In practice, however, different laboratories might interpret this haze ambiguously, potentially misreporting the MIC as $1\\,\\mathrm{mg/L}$ if they were to disregard the trailing. This ambiguity undermines the reproducibility of susceptibility testing. Trailing is often a manifestation of underlying heteroresistance, where a subpopulation of bacteria is less susceptible and grows partially at concentrations that inhibit the bulk population.\n\n3.  **Complication 2: Heteroresistance and Clinical Interpretation:**\n    Heteroresistance is the presence of a minority subpopulation of cells within a larger, isogenic, and more susceptible population that exhibits a higher level of resistance. The problem provides two key pieces of evidence for heteroresistance:\n    -   The population analysis profile reveals a subpopulation surviving up to $4\\,\\mathrm{mg/L}$ at a frequency of approximately $10^{-6}$. In a standard inoculum of $5 \\times 10^{5}\\,\\mathrm{CFU/mL}$ in a well of, for example, $0.1\\,\\mathrm{mL}$, there are $5 \\times 10^4$ initial cells. The expected number of resistant cells per well would be $(5 \\times 10^4\\,\\mathrm{cells}) \\times 10^{-6} \\approx 0.05\\,\\mathrm{cells}$. This is a stochastic event; many wells might contain zero resistant cells, while some might contain one or more.\n    -   The repeat read at $24\\,\\mathrm{h}$ shows growth emerging at concentrations that were clear at $18\\,\\mathrm{h}$ (\"faint film at $2\\,\\mathrm{mg/L}$ and rare pinpoint colonies at $4\\,\\mathrm{mg/L}$\"). This demonstrates that a small number of resistant cells, initially undetectable, were present and required more time to multiply to a visible density.\n\n    This phenomenon severely complicates the application of clinical breakpoints. The breakpoint for susceptibility is given as $B_{S} \\leq 1\\,\\mathrm{mg/L}$.\n    -   With our correctly determined MIC of $2\\,\\mathrm{mg/L}$ (from the $18\\,\\mathrm{h}$ read), we have $\\mathrm{MIC} > B_{S}$. The isolate is correctly classified as **Resistant**. This classification is clinically crucial, as it warns the clinician that therapy with Agent X is likely to fail, especially in an immunocompromised patient. The resistant subpopulation, though initially small, can be selected for under antibiotic pressure *in vivo*, leading to therapeutic failure.\n    -   The complication arises because the standard test is poised at the very limit of its detection capability for such subpopulations. If the resistant subpopulation were slightly less frequent, or grew slightly slower, it might not be detected at all within the standard $16-20\\,\\mathrm{h}$ window. If an ambiguous reading of the trailing at $1\\,\\mathrm{mg/L}$ led to an incorrect MIC report of $1\\,\\mathrm{mg/L}$, the organism would be misclassified as **Susceptible** ($\\mathrm{MIC} \\leq B_{S}$). This could have catastrophic clinical consequences.\n\nIn summary, the MIC determined by the strict application of the standard method at the prescribed time is $2\\,\\mathrm{mg/L}$. However, the phenomena of trailing and heteroresistance, revealed by the hazy endpoint and the delayed growth at $24\\,\\mathrm{h}$, highlight the limitations of this standardized snapshot. They demonstrate that the bacterial population is not uniform and possesses a resistant reservoir that, while not immediately obvious, is responsible for the organism exceeding the susceptibility breakpoint and posing a significant clinical threat. The standardization of inoculum and read time is a pragmatic solution to ensure reproducibility, but it inherently struggles with accurately capturing the full resistance potential of heterogeneous populations like *P. aeruginosa*.", "answer": "$$\\boxed{2}$$", "id": "4686043"}, {"introduction": "Understanding the phenotype of resistance, such as an elevated MIC, requires delving into the underlying cellular mechanisms. This practice explores how *P. aeruginosa* resists carbapenems by downregulating outer membrane porins like OprD, which restricts drug entry. Through developing a transport-limited steady-state model, you will derive a quantitative relationship between the number of porins and the resulting MIC, providing a powerful framework for linking cellular structure to antibiotic efficacy [@problem_id:4686132].", "problem": "Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen that causes ventilator-associated pneumonia among other infections. Carbapenems, such as imipenem, inhibit cell wall synthesis by binding Penicillin-Binding Proteins (PBPs) located in the periplasm. In Gram-negative bacteria, uptake of carbapenems is limited by transport through outer membrane porins, such as Outer membrane porin D (OprD). Consider a transport-limited steady-state model in which the free periplasmic carbapenem concentration $C_{p}$ is determined by porin-mediated influx and by linear removal processes. Assume the following foundational facts: (i) porin-mediated influx follows a linear transport law proportional to porin count, with $N_{p}$ porins each contributing single-channel permeability $k_{p}$ so that the net influx is $J_{\\text{in}} = N_{p} k_{p} \\left(C_{e} - C_{p}\\right)$ where $C_{e}$ is the external antibiotic concentration; (ii) efflux and enzymatic hydrolysis in the periplasm remove free drug by first-order processes with rate constants $k_{e}$ and $k_{h}$, respectively; (iii) binding of carbapenem to PBPs is at rapid equilibrium with dissociation constant $K_{d}$, and the fraction of PBPs occupied is $\\theta = \\frac{C_{p}}{C_{p} + K_{d}}$; (iv) inhibition of growth requires occupancy at or above a threshold $\\theta^{*}$, and binding capacity is non-limiting so that the threshold condition is fully determined by $C_{p}$ and $K_{d}$. \n\nStarting from these bases, derive an expression for the external Minimal Inhibitory Concentration (MIC), denoted $C_{e,\\text{MIC}}$, required to reach the occupancy threshold $\\theta^{*}$ at steady state. Then, consider downregulation of OprD that reduces porin number by a factor $r$ (so $N_{p} \\mapsto r N_{p}$ with $0 < r < 1$). Using the derived expression, compute the fold-change in MIC, defined as $\\frac{C_{e,\\text{MIC}}(r)}{C_{e,\\text{MIC}}(1)}$, for the following parameter values: $N_{p} k_{p} = 1.0\\,\\text{s}^{-1}$, $k_{e} = 0.1\\,\\text{s}^{-1}$, $k_{h} = 0.1\\,\\text{s}^{-1}$, $r = 0.25$, $\\theta^{*} = 0.80$, and $K_{d} = 4.0\\,\\mu\\text{M}$. Express the final fold-change as a decimal. No rounding instruction is required if the value is exact; if approximation is necessary, round to four significant figures.", "solution": "The problem requires the derivation of the external Minimal Inhibitory Concentration ($C_{e,\\text{MIC}}$) for a carbapenem antibiotic acting on *Pseudomonas aeruginosa*, and subsequently the calculation of the fold-change in this $C_{e,\\text{MIC}}$ upon downregulation of an outer membrane porin. The model is based on a steady-state assumption for the periplasmic drug concentration.\n\nFirst, we establish the mass balance for the free periplasmic carbapenem concentration, $C_p$. At steady state, the rate of change of $C_p$ is zero, which means the rate of drug influx must equal the total rate of drug removal from the periplasm.\nThe rate of influx due to transport through $N_p$ porins is given as $N_p k_p (C_e - C_p)$, where $C_e$ is the external concentration, $k_p$ is the single-channel permeability, and $N_p k_p$ is the overall transport rate constant.\nThe removal processes are efflux and enzymatic hydrolysis, which are described as first-order processes with rate constants $k_e$ and $k_h$, respectively. The total removal rate is thus $(k_e + k_h) C_p$.\n\nAt steady state, we have:\n$$ \\text{Rate of Influx} = \\text{Rate of Removal} $$\n$$ N_p k_p (C_e - C_p) = k_e C_p + k_h C_p $$\n\nWe can solve this equation for the steady-state periplasmic concentration $C_p$:\n$$ N_p k_p C_e - N_p k_p C_p = (k_e + k_h) C_p $$\n$$ N_p k_p C_e = (N_p k_p + k_e + k_h) C_p $$\n$$ C_p = \\frac{N_p k_p}{N_p k_p + k_e + k_h} C_e $$\n\nNext, we determine the critical periplasmic concentration, denoted $C_p^*$, required to achieve the inhibitory threshold of Penicillin-Binding Protein (PBP) occupancy, $\\theta^*$. The relationship between occupancy $\\theta$ and concentration $C_p$ is given by the rapid equilibrium binding equation:\n$$ \\theta = \\frac{C_p}{C_p + K_d} $$\nwhere $K_d$ is the dissociation constant. Inhibition occurs when $\\theta \\ge \\theta^*$. The minimal concentration for this condition, $C_p^*$, corresponds to $\\theta = \\theta^*$.\n$$ \\theta^* = \\frac{C_p^*}{C_p^* + K_d} $$\nSolving for $C_p^*$:\n$$ \\theta^*(C_p^* + K_d) = C_p^* $$\n$$ \\theta^* C_p^* + \\theta^* K_d = C_p^* $$\n$$ \\theta^* K_d = C_p^*(1 - \\theta^*) $$\n$$ C_p^* = K_d \\frac{\\theta^*}{1 - \\theta^*} $$\n\nThe external Minimal Inhibitory Concentration, $C_{e,\\text{MIC}}$, is defined as the external concentration $C_e$ that results in the periplasmic concentration reaching the critical level $C_p^*$ at steady state. We find $C_{e,\\text{MIC}}$ by setting $C_p = C_p^*$ and $C_e = C_{e,\\text{MIC}}$ in our steady-state equation:\n$$ C_p^* = \\frac{N_p k_p}{N_p k_p + k_e + k_h} C_{e,\\text{MIC}} $$\nSolving for $C_{e,\\text{MIC}}$:\n$$ C_{e,\\text{MIC}} = C_p^* \\left( \\frac{N_p k_p + k_e + k_h}{N_p k_p} \\right) = C_p^* \\left( 1 + \\frac{k_e + k_h}{N_p k_p} \\right) $$\nSubstituting the expression for $C_p^*$, we obtain the general expression for $C_{e,\\text{MIC}}$:\n$$ C_{e,\\text{MIC}} = K_d \\left( \\frac{\\theta^*}{1 - \\theta^*} \\right) \\left( 1 + \\frac{k_e + k_h}{N_p k_p} \\right) $$\nThis completes the first part of the derivation.\n\nFor the second part, we consider the effect of porin downregulation, which reduces the porin number by a factor $r$, such that the transport parameter $N_p k_p$ becomes $r(N_p k_p)_{\\text{initial}}$. We are asked to compute the fold-change in MIC, defined as $\\frac{C_{e,\\text{MIC}}(r)}{C_{e,\\text{MIC}}(1)}$, where $C_{e,\\text{MIC}}(1)$ is the MIC for the original strain ($r=1$) and $C_{e,\\text{MIC}}(r)$ is the MIC for the downregulated strain.\n\nLet $P = N_p k_p$ be the transport parameter. The MIC for the downregulated strain with transport parameter $rP$ is:\n$$ C_{e,\\text{MIC}}(r) = K_d \\left( \\frac{\\theta^*}{1 - \\theta^*} \\right) \\left( 1 + \\frac{k_e + k_h}{rP} \\right) $$\nThe MIC for the original strain with transport parameter $P$ is:\n$$ C_{e,\\text{MIC}}(1) = K_d \\left( \\frac{\\theta^*}{1 - \\theta^*} \\right) \\left( 1 + \\frac{k_e + k_h}{P} \\right) $$\nThe fold-change is the ratio of these two expressions:\n$$ \\frac{C_{e,\\text{MIC}}(r)}{C_{e,\\text{MIC}}(1)} = \\frac{K_d \\left( \\frac{\\theta^*}{1 - \\theta^*} \\right) \\left( 1 + \\frac{k_e + k_h}{rP} \\right)}{K_d \\left( \\frac{\\theta^*}{1 - \\theta^*} \\right) \\left( 1 + \\frac{k_e + k_h}{P} \\right)} $$\nThe pre-factors involving $K_d$ and $\\theta^*$ cancel, yielding a simplified expression for the fold-change:\n$$ \\frac{C_{e,\\text{MIC}}(r)}{C_{e,\\text{MIC}}(1)} = \\frac{1 + \\frac{k_e + k_h}{rP}}{1 + \\frac{k_e + k_h}{P}} $$\n\nFinally, we substitute the given numerical values to compute the fold-change. The parameters are:\nInitial transport parameter $P = N_p k_p = 1.0\\,\\text{s}^{-1}$.\nEfflux rate constant $k_e = 0.1\\,\\text{s}^{-1}$.\nHydrolysis rate constant $k_h = 0.1\\,\\text{s}^{-1}$.\nDownregulation factor $r = 0.25$.\nThe other parameters, $\\theta^* = 0.80$ and $K_d = 4.0\\,\\mu\\text{M}$, are not needed for this ratio.\n\nFirst, calculate the sum of the removal rate constants:\n$$ k_e + k_h = 0.1\\,\\text{s}^{-1} + 0.1\\,\\text{s}^{-1} = 0.2\\,\\text{s}^{-1} $$\nNow, substitute the values into the fold-change expression:\n$$ \\text{Fold-change} = \\frac{1 + \\frac{0.2}{0.25 \\times 1.0}}{1 + \\frac{0.2}{1.0}} $$\n$$ \\text{Fold-change} = \\frac{1 + \\frac{0.2}{0.25}}{1 + 0.2} $$\n$$ \\text{Fold-change} = \\frac{1 + 0.8}{1.2} $$\n$$ \\text{Fold-change} = \\frac{1.8}{1.2} $$\nThis simplifies to:\n$$ \\text{Fold-change} = \\frac{18}{12} = \\frac{3}{2} = 1.5 $$\nThe fold-change in MIC is exactly $1.5$.", "answer": "$$\\boxed{1.5}$$", "id": "4686132"}, {"introduction": "Ultimately, laboratory data and mechanistic understanding must be translated into effective patient treatment. This final practice bridges the gap from the lab-derived MIC to the clinic by applying pharmacokinetic/pharmacodynamic (PK/PD) principles to optimize therapy. You will determine a precise, patient-specific aminoglycoside dose designed to achieve a bactericidal target ($C_{\\max}/\\mathrm{MIC} \\ge 8$) against *P. aeruginosa* while adhering to safety constraints, illustrating the quantitative approach essential for managing challenging infections [@problem_id:4686068].", "problem": "An adult intensive care unit patient with ventilator-associated pneumonia due to multidrug-susceptible Pseudomonas aeruginosa is being considered for once-daily intravenous amikacin as part of combination therapy. For concentration-dependent aminoglycoside activity, the pharmacokinetic/pharmacodynamic index of interest is the ratio of maximum concentration to Minimum Inhibitory Concentration (MIC), denoted $C_{\\max}/\\mathrm{MIC}$, and a target of $C_{\\max}/\\mathrm{MIC} \\ge 8$ is desired to maximize bacterial kill and suppress resistance emergence. Assume a one-compartment model with rapid intravenous administration and immediate distribution into the central compartment. The patient has a weight of $70\\,\\mathrm{kg}$ and an estimated volume of distribution of $V_{d} = 0.25\\,\\mathrm{L/kg}$. The pathogen’s Minimum Inhibitory Concentration (MIC) to amikacin is $2\\,\\mathrm{mg/L}$.\n\nTo limit nephrotoxicity risk, institutional policy caps the single-dose aminoglycoside exposure at $15\\,\\mathrm{mg/kg}$ per administration. Compute the smallest single amikacin dose that achieves $C_{\\max}/\\mathrm{MIC} \\ge 8$ while respecting the nephrotoxicity constraint. Express your final dose in milligrams and round your answer to three significant figures.", "solution": "The problem statement has been critically evaluated and is determined to be valid. It is scientifically grounded in the principles of clinical pharmacokinetics and pharmacodynamics, is well-posed, and contains all necessary information to derive a unique and meaningful solution. The parameters provided, such as the volume of distribution for amikacin, the Minimum Inhibitory Concentration (MIC) for *Pseudomonas aeruginosa*, and the therapeutic target ratio, are all within realistic clinical ranges.\n\nThe objective is to find the smallest single dose of amikacin that satisfies a therapeutic target while adhering to a safety constraint. The problem states that the pharmacokinetic behavior of the drug can be described by a one-compartment model with rapid intravenous administration. In this model, the initial concentration immediately after the dose is administered represents the maximum concentration, $C_{\\max}$. This concentration is calculated by dividing the administered dose by the patient's volume of distribution, $V_d$.\n\nThe relationship is given by the equation:\n$$C_{\\max} = \\frac{\\text{Dose}}{V_d}$$\n\nFirst, we must calculate the patient's total volume of distribution, $V_d$. The problem provides a weight-based volume of distribution of $0.25\\,\\mathrm{L/kg}$ and the patient's weight, $W$, as $70\\,\\mathrm{kg}$.\n$$V_d = (0.25\\,\\mathrm{L/kg}) \\times W$$\n$$V_d = (0.25\\,\\mathrm{L/kg}) \\times 70\\,\\mathrm{kg} = 17.5\\,\\mathrm{L}$$\n\nNext, we identify the therapeutic target. The problem specifies that the ratio of the maximum concentration to the Minimum Inhibitory Concentration, $C_{\\max}/\\mathrm{MIC}$, must be greater than or equal to $8$.\n$$\\frac{C_{\\max}}{\\mathrm{MIC}} \\ge 8$$\nTo find the smallest dose that achieves this target, we solve for the exact case where the ratio is equal to $8$.\n$$\\frac{C_{\\max}}{\\mathrm{MIC}} = 8$$\nThe problem states the pathogen's MIC is $2\\,\\mathrm{mg/L}$. We can use this to calculate the required target $C_{\\max}$.\n$$C_{\\max}^{\\text{target}} = 8 \\times \\mathrm{MIC} = 8 \\times 2\\,\\mathrm{mg/L} = 16\\,\\mathrm{mg/L}$$\n\nNow, we can calculate the dose required to achieve this target $C_{\\max}$ of $16\\,\\mathrm{mg/L}$ in a patient with a volume of distribution of $17.5\\,\\mathrm{L}$. Rearranging the initial equation:\n$$\\text{Dose} = C_{\\max}^{\\text{target}} \\times V_d$$\n$$\\text{Dose} = 16\\,\\mathrm{mg/L} \\times 17.5\\,\\mathrm{L} = 280\\,\\mathrm{mg}$$\nThis calculated dose of $280\\,\\mathrm{mg}$ is the minimum required to satisfy the condition $C_{\\max}/\\mathrm{MIC} \\ge 8$. Any dose lower than this would result in a $C_{\\max}/\\mathrm{MIC}$ ratio less than $8$.\n\nThe final step is to verify that this calculated dose respects the institutional nephrotoxicity constraint, which caps the single dose at $15\\,\\mathrm{mg/kg}$. We calculate the maximum allowed dose for this patient:\n$$\\text{Dose}_{\\max} = (15\\,\\mathrm{mg/kg}) \\times W = (15\\,\\mathrm{mg/kg}) \\times 70\\,\\mathrm{kg} = 1050\\,\\mathrm{mg}$$\nThe calculated required dose is $280\\,\\mathrm{mg}$, which is less than the maximum allowed dose of $1050\\,\\mathrm{mg}$.\n$$280\\,\\mathrm{mg} \\le 1050\\,\\mathrm{mg}$$\nSince the required dose is within the safety limit, it is an acceptable dose.\n\nThe problem asks for the smallest dose that meets the criteria, which is the $280\\,\\mathrm{mg}$ we calculated. The problem also specifies to round the answer to three significant figures. The number $280$ can be written as $2.80 \\times 10^2$, which has three significant figures. Therefore, the value $280$ is already presented to the correct number of significant figures, and no further rounding is necessary.", "answer": "$$\\boxed{280}$$", "id": "4686068"}]}